[HTML][HTML] Evaluation of Erythropoietin Stimulating Agent's Responsiveness and Associated Factors in Hemodialysis Patients with Anemia
SA Alzubaidy, MM Mohammed… - Medical Journal of …, 2024 - journals.lww.com
Background: Chronic kidney disease (CKD) patients often develop erythropoietin-deficient
anemia. Erythropoietin stimulating agents (ESAs) are the conventional treatment for CKD …
anemia. Erythropoietin stimulating agents (ESAs) are the conventional treatment for CKD …
[PDF][PDF] Association of Dialysis Adequacy, Physical and Emotional Symptoms with Erythropoietin-stimulating agent Responsiveness in Iraqi Patients Undergoing …
S Ahmed, MM Mohammed, A Sami, S Hamadi - AJPS, 2024 - iasj.net
Background: Erythropoietin (EPO)-deficient anemia occurs in patients with chronic kidney
disease (CKD). Erythropoietinstimulating agents (ESAs) are the standard treatment for CKD …
disease (CKD). Erythropoietinstimulating agents (ESAs) are the standard treatment for CKD …
Usefulness of Platelet to Lymphocyte Ratio as a marker of Erythropoietin Resistance in Hemodialysis Patients
H ELSheikh, A Fathy, MK Azab… - The Egyptian Journal of …, 2023 - ejhm.journals.ekb.eg
Background: Chronic inflammation was associated with the hyporesponsiveness to
erythropoiesis stimulating agents (ESA) in hemodialysis (HD) patients. A rising indicator of …
erythropoiesis stimulating agents (ESA) in hemodialysis (HD) patients. A rising indicator of …